课题基金 / 基金详情

Development of Faster, Lower-Cost, High-Sensitivity Immunoassay for Specific Determination of Glucagon Using EAP-derived Monoclonal Antibodies

Development of Faster, Lower-Cost, High-Sensitivity Immunoassay for Specific Determination of Glucagon Using EAP-derived Monoclonal Antibodies
使用 EAP 衍生的单克隆抗体开发更快、成本更低、高灵敏度的免疫测定法,用于特异性测定胰高血糖素
批准号:
9107441
负责人:
MARK GEISBERG
金额:
$22.01万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-08-01 至 2018-01-31

项目摘要

项目成果

MARK GEISBERG的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(由申请人提供):胰高血糖素是一种肽激素,在葡萄糖代谢的调节中起核心作用,许多疾病,包括1型和2型糖尿病,都以胰高血糖素水平异常为特征。该领域的临床实践和研究都受到缺乏血液中胰高血糖素水平的适当特异性和灵敏度测定的阻碍。该项目的目标是开发和验证用于胰高血糖素测定的改进的免疫测定法,使用最近制造的胰高血糖素超特异性单克隆抗体。这些检测方法提供的新功能可以使人们对葡萄糖稳态紊乱的理解取得重大进展,同时也可以对这种关键激素进行准确的临床检测。
英文摘要
 DESCRIPTION (provided by applicant): Glucagon is a peptide hormone with a central role in the regulation of glucose metabolism, and many disorders, including Type 1 and Type 2 diabetes, are notable for abnormalities in glucagon levels. Both clinical practice and research in this field are hampered by the lack of appropriately specific and sensitive assays for glucagon levels in blood. The goal of this project is to develop and validate improved immunoassays for glucagon determination, using recently made hyperspecific monoclonal antibodies to glucagon. The new capabilities offered by these assays can lead to significant advances in the understanding of glucose homeostasis disorders and, in parallel, enable accurate clinical testing for this crucial hormone.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EAP-Derived Monoclonal Antibodies for Phenotyping Immune Cells of Animal Model of Disease
  • 批准号:
    10933282
  • 项目类别:
  • 资助金额:
    $75.0万
  • 财政年份:
    2023
  • 负责人:
    MARK GEISBERG
  • 依托单位:
A Rapid and Inexpensive Point-of-Care Test for Beta-Thalassemia Carriers
  • 批准号:
    10053692
  • 项目类别:
  • 资助金额:
    $34.85万
  • 财政年份:
    2020
  • 负责人:
    MARK GEISBERG
  • 依托单位:
EAP-DERIVED MONOCLONAL ANTIBODIES FOR PHENOTYPING GUINEA PIG IMMUNE CELLS.
  • 批准号:
    10291475
  • 项目类别:
  • 资助金额:
    $60.0万
  • 财政年份:
    2020
  • 负责人:
    MARK GEISBERG
  • 依托单位:
Rapid LFIA blood test for SCD using highly specific monoclonal antibodies
  • 批准号:
    9170967
  • 项目类别:
  • 资助金额:
    $50.0万
  • 财政年份:
    2014
  • 负责人:
    MARK GEISBERG
  • 依托单位:
海外基金